{
    "id": 6067,
    "name": "ovarian mucinous neoplasm",
    "source": "DOID",
    "definition": "An ovary epithelial cancer that is characterized by the presence of mucin. [url:https\\://en.wikipedia.org/wiki/Ovarian_mucinous_tumor]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "3712"
    ],
    "termId": "DOID:6067",
    "evidence": [
        {
            "id": 5905,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 786,
                "therapyName": "KX2-391",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5906,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 683,
                "profileName": "PTEN wild-type"
            },
            "therapy": {
                "id": 3979,
                "therapyName": "KX2-391 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5907,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 786,
                "therapyName": "KX2-391",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5908,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",
            "molecularProfile": {
                "id": 4015,
                "profileName": "PTEN G129R"
            },
            "therapy": {
                "id": 786,
                "therapyName": "KX2-391",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5909,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 3979,
                "therapyName": "KX2-391 + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 6067,
                "name": "ovarian mucinous neoplasm",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5193,
                    "pubMedId": 24100628,
                    "title": "Targeting SRC and tubulin in mucinous ovarian carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24100628"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03476681",
            "title": "QUILT-3.017: Study of NEO-201 in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7808,
                    "therapyName": "NEO-201",
                    "synonyms": null
                }
            ]
        }
    ]
}